The stock of PRA Health Sciences Inc (NASDAQ:PRAH) reached all time high today, Oct, 10 and still has $80.08 target or 37.00% above today’s $58.45 share price. This indicates more upside for the $3.64B company. This technical setup was reported by Barchart.com. If the $80.08 PT is reached, the company will be worth $1.35 billion more.
Trading stocks at an all time highs is usually a winning strategy. An all time high points to a stock which has the most positive fundamentals ever. Even thought the pullback rate is high, if correct risk management is utilized, investors can trade very well such events. About 100,488 shares traded hands. PRA Health Sciences Inc (NASDAQ:PRAH) has risen 33.46% since March 7, 2016 and is uptrending. It has outperformed by 25.87% the S&P500.
Analysts await PRA Health Sciences Inc (NASDAQ:PRAH) to report earnings on November, 7. They expect $0.62 EPS, up 24.00% or $0.12 from last year’s $0.5 per share. PRAH’s profit will be $38.61 million for 23.57 P/E if the $0.62 EPS becomes a reality. After $0.61 actual EPS reported by PRA Health Sciences Inc for the previous quarter, Wall Street now forecasts 1.64% EPS growth.
PRA Health Sciences Inc (NASDAQ:PRAH) Ratings Coverage
Out of 9 analysts covering PRA Health Sciences (NASDAQ:PRAH), 5 rate it a “Buy”, 0 “Sell”, while 4 “Hold”. This means 56% are positive. PRA Health Sciences has been the topic of 13 analyst reports since July 22, 2015 according to StockzIntelligence Inc. The firm has “Neutral” rating by SunTrust given on Thursday, November 19. The firm has “Equal-Weight” rating given on Tuesday, June 21 by First Analysis. The firm has “Buy” rating by Citigroup given on Wednesday, May 4. The firm has “Neutral” rating given on Thursday, November 19 by Suntrust Robinson. The company was upgraded on Monday, June 13 by KeyBanc Capital Markets. UBS downgraded the stock to “Neutral” rating in Tuesday, September 6 report. As per Thursday, September 22, the company rating was maintained by Citigroup. Credit Suisse initiated PRA Health Sciences Inc (NASDAQ:PRAH) on Tuesday, June 21 with “Neutral” rating. The company was upgraded on Monday, March 28 by SunTrust. The stock of PRA Health Sciences Inc (NASDAQ:PRAH) earned “Outperform” rating by Credit Suisse on Friday, August 14.
According to Zacks Investment Research, “PRA Health Sciences, Inc. operates as a global contract research organizations providing outsourced clinical development services to the biotechnology and pharmaceutical industries. It offers therapeutic services in the areas of cardio-metabolic, biosimilars, infectious diseases, immunology, neurology and psychiatry, oncology and hematology, rare diseases, and respiratory needs. The Company engages in bioanalytical laboratory, clinical pharmacology, clinical development, strategic solutions, post marketing research, clinical informatics, clinical diagnostics, and safety and risk management activities. PRA Health Sciences, Inc. is based in Raleigh, North Carolina.”
More news for PRA Health Sciences Inc (NASDAQ:PRAH) were recently published by: Businesswire.com, which released: “Takeda and PRA Health Sciences Announce Transformational Clinical Development …” on September 12, 2016. Moodys.com‘s article titled: “Moody’s upgrades PRA Health’s CFR to B1” and published on March 17, 2016 is yet another important article.
PRAH Company Profile
PRA Health Sciences, Inc., incorporated on June 21 2013, is a contract research organization (CRO). The Firm provides outsourced clinical development services to the biotechnology and pharmaceutical industries. The Firm offers therapeutic services in areas of pharmaceutical development, including oncology, central nervous system, inflammation and infectious diseases. The Company’s integrated services include data management, statistical analysis, clinical trial management, and regulatory and drug development consulting. The Firm provides its clients with clinical development service offerings, which includes both traditional, project Phase I through Phase IV services, as well as embedded and functional outsourcing services. The Company’s clinical development platform includes over 70 offices across North America, Europe, Asia, Latin America, South Africa, Australia and the Middle East.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.